Capstone Investment Advisors
BIOT

Capstone Investment Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Capstone Investment Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-118,426
Closed -$1.17M – 2218
2021
Q4 		$1.17M Hold
118,426
– – ﹤0.01% 1262
2021
Q3 		$1.15M Buy
+118,426
New +$1.15M ﹤0.01% 1362

Other funds holding BIOT

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return

Capstone Investment Advisors's BIOT Position: Q1 2022 in Review

Capstone Investment Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2022, closing a stake of 118,426 shares — an estimated $1.17M sold.

Capstone Investment Advisors first reported a position in BIOT in Q3 2021 and held it in 2 quarters. The position peaked at $1.17M in Q4 2021. 76 funds tracked by Wall St. Rank hold BIOT as of Q1 2022.

  • Capstone Investment Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Capstone Investment Advisors sold 118,426 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2022, an estimated $1.17M.
  • Capstone Investment Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 2 quarters.
  • Capstone Investment Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.17M in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2022.

Based on Capstone Investment Advisors's 13F filing for Q1 2022, filed 13 May 2022.